These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36339826)

  • 1. PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis.
    Wang F; Wang FH; Sun K; Jiang C; Peng S; Xu LX; Kuang M; Guo GF; Chen SL
    J Inflamm Res; 2022; 15():6031-6046. PubMed ID: 36339826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Single-center study of different treatment for advanced or unresectable angiosarcoma patients].
    Peng RQ; Xu BS; Liu YY; Yang QQ; Pan QZ; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2023 Jan; 45(1):74-81. PubMed ID: 36709123
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis.
    Jiang Q; Huang J; Zhang B; Li X; Chen X; Cui B; Li S; Guo G
    Front Immunol; 2022; 13():801909. PubMed ID: 35309350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective cohort study on the efficacy and safety for combination therapy of immunotherapy, targeted agent, and chemotherapy versus immunochemotherapy or chemotherapy alone in the first-line treatment of advanced biliary tract carcinoma.
    Zeng J; Ma J; Zeng Z; Yang L; Jiang Y; Mo N; Ma F; Liu C; Li R; Tang J; Qin S; Jiang H
    J Gastrointest Oncol; 2023 Apr; 14(2):758-767. PubMed ID: 37201053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival benefit and biomarker of PD-1 inhibitor combination therapy in first-line of advanced biliary tract cancer: A retrospective study.
    Guo J; Zhou Q; Zhou M; Dai H; Li L; Qiu Y; Mao L; Liu B; Shen J
    Cancer Med; 2023 Nov; 12(22):20699-20711. PubMed ID: 37930138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
    He Y; Gao Y; Ping L; He H; Huang C; Bai B; Wang X; Li Z; Cai Q; Huang Y; Pan X; Zeng W; Liu Y; Huang H
    J Cancer Res Clin Oncol; 2023 May; 149(5):2017-2027. PubMed ID: 35809114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mFOLFOX-HAIC+lenvatinib+PD-1 inhibitors versus GC/GS/GEMOX chemotherapy as a first line therapy for advanced biliary tract cancer: A single-center retrospective cohort study.
    Sun Z; Xu H; Yang L; Wang X; Shu B; Yang M; Ren Z; Xiang C; Zhang Y; Yang S
    Biosci Trends; 2024 Oct; ():. PubMed ID: 39401897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study.
    Wang Y; Yang X; Wang Y; Xue J; Zhang N; Yang X; Cong N; Zhang J; Zhu C; Zhang L; Hou X; Zhao H
    Cancer Immunol Immunother; 2023 Jul; 72(7):2197-2204. PubMed ID: 36856834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer.
    Cui Q; Mao Y; Wu D; Hu Y; Ma D; Zhang L; Liu H
    Front Oncol; 2022; 12():952494. PubMed ID: 36387189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A real-world study of the efficacy and safety of anti-programmed cell death-1 therapy combined with chemotherapy or targeted therapy in patients with advanced biliary tract cancer.
    Sun D; Ma J; Wang J; Wang L; Zhang S; Chen G; Li X; Cui P; Zheng X; Hu Y
    J Gastrointest Oncol; 2020 Dec; 11(6):1421-1430. PubMed ID: 33457011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anatomical classification of advanced biliary tract cancer predicts programmed cell death protein 1 blockade efficacy.
    Huang L; Wang F; Wang F; Jiang Q; Huang J; Li X; Guo G
    Front Pharmacol; 2024; 15():1375769. PubMed ID: 39281274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.
    Deng YY; Zhang XY; Zhu PF; Lu HR; Liu Q; Pan SY; Chen ZL; Yang L
    Front Oncol; 2023; 13():1097911. PubMed ID: 36937443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer.
    Sun D; Ma J; Wang J; Han C; Qian Y; Chen G; Li X; Zhang J; Cui P; Du W; Wu Z; Chen S; Zheng X; Yue Z; Song J; Gao C; Zhao X; Cai S; Hu Y
    Cancer Immunol Immunother; 2019 Sep; 68(9):1527-1535. PubMed ID: 31535160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of immunotherapy in
    Peng L; Guo J; Kong L; Huang Y; Tang N; Zhang J; Wang M; He X; Li Z; Peng Y; Wang Z; Han X
    Front Oncol; 2022; 12():1070761. PubMed ID: 36741723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of camrelizumab combined with chemotherapy in the treatment of advanced biliary malignancy and associations between peripheral blood lymphocyte subsets and clinical outcomes.
    Zhao J; Guo H; Wu C; Guo H
    Clin Transl Oncol; 2024 Sep; ():. PubMed ID: 39294513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma.
    Huang D; Cui P; Huang Z; Wu Z; Tao H; Zhang S; Xiang R; Hu Y
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):881-891. PubMed ID: 32909095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research.
    Meng Y; Yang Y; Fang Y; Lin X; Xie X; Deng H; Wu J; Zhou M; Sun N; Xie Z; Liu M; Ouyang M; Qin Y; Su C; Zhou C
    Front Oncol; 2022; 12():864367. PubMed ID: 35692799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
    Kus T; Aktas G; Kalender ME; Sevinc A; Camci C
    J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China.
    Peng W; Zhang F; Wang Z; Li D; He Y; Ning Z; Sheng L; Wang J; Xia X; Yu C; Wang Z; Zhao Y; Liang H; Hu B; Sun C; Wang D; Cheng Y; Pan M; Xia L; Guo X; Zhang Y; Hu Z; Li X; Lu L; Zhang J; Qian H; Xie H; Sun G
    Cancer Manag Res; 2020; 12():6977-6985. PubMed ID: 32821164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer.
    Wang F; Guo GF; Qiu HJ; He WZ; Zhou FF; Chen XX; Hu PL; Zhang B; Yin CX; Zhang L; Xia LP
    Cancer Biol Med; 2012 Mar; 9(1):38-43. PubMed ID: 23691453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.